Proven across a broad range of complex case types, the versatility of the GORE® VIABAHN® Endoprosthesis enables you to deliver high patency and durable outcomes to minimize interventions for your patients.

  • Reduced interventions. Proven success in the most challenging AV Access cases.
  • High patency. Proven patency in complex SFA lesions.
  • Demonstrated durability. Superior outcomes in the treatment of in-stent restenosis.
  • Proven safety and efficacy. Only self-expanding stent graft indicated to treat iliac lesions.

Backed by a growing body of clinical data, the Gore® VIABAHN® Endoprosthesis has become a go-to device for physicians’ most challenging cases.

Over 2,000 scientific publications
(data on file 2017; W. L. Gore & Associates, Inc; Flagstaff, AZ.)

Over 5,150 hospitals using GORE® VIABAHN® Endoprosthesis
(data on file 2017; W. L. Gore & Associates, Inc; Flagstaff, AZ.)

Over 500,000 implanted in patients worldwide
(data on file 2017; W. L. Gore & Associates, Inc; Flagstaff, AZ.)


Performance evolution through collaboration

Since 1996, performance of the GORE® VIABAHN® Endoprosthesis has continuously evolved, maximizing device performance and delivering durable outcomes, reduced interventions, high patency, and proven safety and efficacy. Now featuring:

  • Lengths up to 25 cm
  • Low profile design
  • Multiple indications for use
  • Radiopaque markers
  • Proven CBAS Heparin Surface* technology**

     

* Heparin Bioactive Surface is synonymous with the CBAS Heparin Surface.

** See full CBAS Heparin Surface references at goremedical.com/cbas

GORE VIABAHN Endoprosthesis - Heparin Bioactive Surface